Principle Investigator, PROTEOMIC AND GENOMIC PROFILES OF INTRADUCTAL MUCINOSA PAPILLARY NEOPLASMS, William Beaumont Hospital BioBank.
In collaboration with George Wilson, PhD, and the Erb BioBank/Beaumont Health System, Dr. Jury is involved in research to discover genetic markers which may be helpful in the early detection of pancreatic cancer. The results of their early work were presented to an international audience at the annual meeting of the in New Orleans, LA in May, 2010 and published in the Pancreas Journal, May, 2012, “Gene Expression Changes Associated With the Progression of Intraductal Papillary Mucinous Neoplasms”
Many of Dr. Jury’s patients have had the opportunity to participate in this important research by contributing samples at the time of surgery. This has allowed our team of scientists to study genetic changes in various pancreatic conditions, and to identify genes that may be involved in cancer development.
Sub Investigator, A PHASE III STUDY OF CHEMOTHERAPY AND CHEMORADIOTHERAPY WITH OR WITHOUT HYPERACUTE®-PANCREATIC VACCINE IN SUBJECTS WITH SURGICALLY RESECTED PANCREATIC CANCER (NEW LINK GENETICS). HIC 10-053.
Along with Dr. Laura Nadeau, principle investigator, Dr. Jury has also been actively involved in research to study the effects of a newly developed pancreatic cancer vaccine for patients who have undergone successful surgical removal of their pancreatic cancer.